Sen-Jam Pharmaceutical has initiated a Phase 2 clinical trial for its pioneering hangover prevention therapy, SJP-001, now underway in Canada with global research partner Cliantha. This milestone positions SJP-001 to become the first FDA therapy to directly target the inflammatory root cause of alcohol-induced symptoms—moving beyond surface-level relief like hydration. It also represents a flagship validation of Sen-Jam's PAIR Technology (Preemptive Anti-Inflammatory Regulators) platform—a scalable, modular technology designed to unlock next-generation broad spectrum anti-inflammatory therapies for a wide range of inflammation-driven conditions with massive unmet needs.
SJP-001 is protected by 23 global patents and built on a novel combination of repurposed drugs designed to safely disrupt the inflammatory cascade triggered by alcohol consumption. Unlike surface-level remedies, SJP-001 targets the biological driver of hangover symptoms—offering a scientifically grounded, first-in-class approach.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!